Sarepta announces filing of New Drug Application for Duchenne muscular dystrophy treatment
Sarepta Therapeutics Inc., a developer of RNA-targeted therapeutics, on Tuesday announced that the U.S. Food and Drug Administration (FDA) has filed the New Drug Application for eteplirsen for the treatment of Duchenne muscular dystrophy amenable to exon 51 skipping. Read More »